Biogen Idec 8-K 2005
Washington, D.C. 20549
Date of Report (Date of earliest event reported): February 28, 2005
Biogen Idec Inc.
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (617) 679-2000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01 Other Events
On February 28, 2005, the Registrant publicly disseminated a press release announcing a voluntary suspension in the marketing and commercial distribution of TYSABRI® (natalizumab), a treatment for multiple sclerosis, and that physicians should suspend dosing of TYSABRI until further notification. The press release also announced that dosing of TYSABRI would be suspended in all clinical trials. The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 3, 2005